Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Share-based Compensation: 2016-2024

Historic Share-based Compensation for Whitehawk Therapeutics (WHWK) over the last 9 years, with Dec 2024 value amounting to $10.8 million.

  • Whitehawk Therapeutics' Share-based Compensation rose 6.30% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 22.79%. This contributed to the annual value of $10.8 million for FY2024, which is 9.33% down from last year.
  • As of FY2024, Whitehawk Therapeutics' Share-based Compensation stood at $10.8 million, which was down 9.33% from $12.0 million recorded in FY2023.
  • Whitehawk Therapeutics' 5-year Share-based Compensation high stood at $12.0 million for FY2023, and its period low was $139,000 during FY2020.
  • Over the past 3 years, Whitehawk Therapeutics' median Share-based Compensation value was $10.8 million (recorded in 2024), while the average stood at $10.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 87.20% in 2020, then skyrocketed by 1,415.11% in 2021.
  • Whitehawk Therapeutics' Share-based Compensation (Yearly) stood at $139,000 in 2020, then skyrocketed by 1,415.11% to $2.1 million in 2021, then spiked by 357.88% to $9.6 million in 2022, then rose by 23.97% to $12.0 million in 2023, then fell by 9.33% to $10.8 million in 2024.